ArticleKidney international2013
Urine haptoglobin levels predict early renal functional decline in patients with type 2 diabetes.
Article in Kidney international, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00256646 (CSP #465D - Markers And Mechanisms of Vascular Disease in Type II Diabetes), which is not on this map. Cited by 33 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
CSP #465D - Markers And Mechanisms of Vascular Disease in Type II Diabetes
Who cites it
33 citing papers in PubMed, 81 citations in OpenAlex.
- Haptoglobin phenotype and levels in type 2 diabetes and effects of fenofibrate.Journal of diabetes investigation · 2024Trial
- Urinary biomarkers of diabetic kidney disease.World journal of diabetes · 2026Review
- Clinical Association of Haptoglobin with Oxidized LDL in Obese Patients with Type 2 Diabetes Mellitus.Nutrients · 2025Article
- The Urinary Glycopeptide Profile Differentiates Early Cardiorenal Risk in Subjects Not Meeting Criteria for Chronic Kidney Disease.International journal of molecular sciences · 2024Article
- Insulin and the kidneys: a contemporary view on the molecular basis.Frontiers in nephrology · 2023Review
- Novel biomarkers for diabetic kidney disease.Kidney research and clinical practice · 2022Article
- Selonsertib Enhances Kidney Protection Beyond Standard of Care in a Hypertensive, Secondary Glomerulosclerosis CKD Model.Kidney360 · 2022Article
- Pathophysiologic Mechanisms and Potential Biomarkers in Diabetic Kidney Disease.Diabetes & metabolism journal · 2022Review
- Early renal structural changes and potential biomarkers in diabetic nephropathy.Frontiers in physiology · 2022Review
- Molecular profiling of urinary extracellular vesicles in chronic kidney disease and renal fibrosis.Frontiers in pharmacology · 2022Review
- Integrative Biology of Diabetic Retinal Disease: Lessons from Diabetic Kidney Disease.Journal of clinical medicine · 2021Review
- Review
- Diabetic kidney diseases revisited: A new perspective for a new era.Molecular metabolism · 2019Review
- Article
- iTRAQ plasma proteomics analysis for candidate biomarkers of type 2 incipient diabetic nephropathy.Clinical proteomics · 2019Article
- Urinary Proteomics for the Early Diagnosis of Diabetic Nephropathy in Taiwanese Patients.Journal of clinical medicine · 2018Article
- Biomarkers of diabetic kidney disease.Diabetologia · 2018Review
- Genetic markers for urine haptoglobin is associated with decline in renal function in type 2 diabetes in East Asians.Scientific reports · 2018Article
- The Promise of Systems Biology for Diabetic Kidney Disease.Advances in chronic kidney disease · 2018Review
- Urinary Proteome Analysis Identified Neprilysin and VCAM as Proteins Involved in Diabetic Nephropathy.Journal of diabetes research · 2018Article
Corrections and comments
- Commented on by
Authors and funding
10 authors at 1 institution in 1 country.
Funding
Abstract
Diabetic nephropathy is the leading cause of end-stage renal disease. The urinary albumin to creatinine ratio is used as a predictor for the development of nephropathy but it is neither sensitive nor specific. Here we used liquid chromatography/mass spectrometry on urine of eight normoalbuminuric patients with type 2 diabetes from the VA Diabetes Trial to identify candidate markers for loss of renal function. Initial verification of seven markers (agrin, haptoglobin, mannan-binding lectin serine protease 2, LAMP-2, angiotensinogen, NGAL, and uromodulin) in the urine of an additional 30 patients showed that haptoglobin was the best predictor of early renal functional decline. We then measured this in the urine of 204 patients with type 2 diabetes who did not yet have significant kidney disease (estimated glomerular filtration rate stage 2 or better and an albumin to creatinine ratio <300 mg/g). In comparing the highest to lowest tertiles, the odds ratio for having early renal function decline was 2.70 (CI: 1.15, 6.32) using the haptoglobin to creatinine ratio compared with 2.50 (CI 1.14, 5.48) using the albumin to creatinine ratio after adjusting for treatment group and use of ACE inhibitors. Addition of the haptoglobin to creatinine ratio to a model using the albumin to creatinine ratio to predict early renal function decline resulted in improved predictive performance. Thus, the haptoglobin to creatinine ratio may be useful to predict patients with type 2 diabetes at risk of nephropathy before the development of macroalbuminuria or reduced glomerular filtration rate.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.